In clinical practice, these tumors are classified as triple-negative BC (TNBC) or, if hormone receptors (HRs) are expressed, as luminal BC, thus being considered to not benefit from anti-HER2 treatments. This evidence concerns the gene ERBB2 and breast cancer.